American Portfolios Advisors Hutchmed (China) LTD Transaction History

American Portfolios Advisors

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Mar 21, 2023	BUY	$15.52 - $35.65 $8,008 - $18,395	516 New	516 $9.76 Million
Q4 2021 Mar 21, 2023	BUY	$28.89 - $35.33 $14,907 - $18,230	516 New	516 $18.1 Million
Q3 2021 Mar 22, 2023	BUY	$35.66 - $42.94 $18,400 - $22,157	516 New	516 $18.9 Million
Q2 2021 Mar 22, 2023	BUY	$23.7 - $39.27 $6,422 - $10,642	271 New	271 $10.6 Million
Q1 2021 Mar 22, 2023	BUY	$27.01 - $36.8 $7,319 - $9,972	271 New	271 $7.66 Million
Q4 2020 Mar 22, 2023	BUY	$27.51 - $34.36 $7,455 - $9,311	271 New	271 $8.68 Million
Q3 2020 Mar 22, 2023	BUY	$25.8 - $34.61 $6,991 - $9,379	271 New	271 $8.75 Million
Q1 2020 Mar 24, 2023	BUY	$15.19 - $29.51 $1,017 - $1,977	67 New	67 $1.2 Million
Q4 2019 Mar 24, 2023	BUY	$17.17 - $25.95 $1,150 - $1,738	67 New	67 $1.68 Million
Q2 2019 Mar 24, 2023	BUY	$22.0 - $31.78 $1,474 - $2,129	67 New	67 $1.47 Million
Q4 2018 Mar 24, 2023	BUY	$23.09 - $37.69 $1,547 - $2,525	67 New	67 $1.55 Million

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

Stay updated on American Portfolios Advisors with notifications on news.